Avoiding Regulatory Setbacks In OSD Development: Why Early Formulation Decisions Matter

When the pressure to reach first-in-human studies is high, formulation decisions can feel like a necessary shortcut. But for biotech innovators developing oral solid dose therapies, early-phase choices made without full visibility into downstream requirements often create the very delays they were meant to avoid. Borderline solubility, inadequate stability data, and poorly characterized APIs may clear preclinical hurdles only to resurface as costly problems during scale-up or regulatory review.

The consequences are significant: an FDA analysis of more than 1,000 IND applications submitted between 2016 and 2021 found that over 350 were placed on clinical hold due to quality-related safety issues, many tied directly to CMC deficiencies. These holds don't just slow timelines; they consume critical resources at pivotal moments in your program. A more strategic approach to formulation planning, one that connects near-term milestones to long-term CMC readiness, can help you avoid these setbacks before they take hold.

Understanding where risk accumulates in early OSD development and how to build a formulation strategy that supports both regulatory readiness and scalability is increasingly a competitive advantage. Read the full article to learn how to strengthen your CMC foundation from the start and protect your program's momentum through every development stage.